ACT Genomics Raises US$ 12.5M in Series B Funding

ACT Genomics, a Taipei, Taiwan-based integrated cancer molecular information company, raised US$ 12.5m in Series B funding.

The round was led by Hotung Group, and CDIB Capital Management with participation from existing investors Eminent II VC, Hua Nan Venture Capital, President International Development and UMC Capital.

The company will use the funds to further boost the capacity to support the growth and expansion in Japan, Taiwan, Singapore, Malaysia, Thailand, and Hong Kong, and ramp up its commercial channels to drive further global expansion, following its move into Asia Pacific region earlier this year.

Led by PJ (Joe) Hsueh, MBA, Chief Operating Officer, ACT Genomics provides comprehensive genomic profiling assays and molecular information to physicians and biopharmaceutical customers as well as clinical services to expand targeted therapy treatment options, predict response to immune-checkpoint inhibitors, and utilize ctDNA based assay to monitor tumor burden and resistant markers, in a CAP-accredited NGS laboratory.



Join the discussion